Date: 2012-06-20
Type of information: Services contract
Compound: drug discovery services
Company: Genfit (France) Imabiotech (France)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: The contract research organization (CRO) ImaBiotech and Genfit, a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…) have announced the initiation of a collaboration and the relocation of ImaBiotech to laboratories within Genfit’s headquarters. This long-term collaboration involves the sharing of technological platforms and mutual drug discovery services.
ImaBiotech has moved into this larger, more secure site to accommodate the most recent addition to their innovative platform, a unique imaging instrument (7 Tesla SolariX, Bruker Daltonics). Furthermore, the relocation enables the company to stay at the heart of the Parc Eurasanté, one of the largest European biopoles, and its extensive business and scientific network.
Financial terms:
Latest news:
